

# Information for Prescribers of Prescription Drugs Provided Pursuant to Colorado HB 19-1131 and Connecticut HB 6669

## Vaccine Products

### Marketed Prescription Drug

### WAC\* Price

Adacel® (0.5 mL dose) Syringe	\$ 244.14 per 5 single-dose syringes
Adacel® (0.5 mL dose) Vial	\$ 488.28 per 10 single-dose vials
BEYFORTUS® (50 mg/0.5 mL dose) Syringe	\$ 2,780.66 per 5 single-dose syringes
BEYFORTUS® (100 mg/mL dose) Syringe	\$ 2,780.66 per 5 single-dose syringes
Flublok® Trivalent (0.5 mL dose) Syringe	\$ 854.80 per 10 single-dose syringes
Fluzone® High-Dose Trivalent (0.5 mL dose) Syringe	\$ 854.80 per 10 single-dose syringes
Fluzone® Trivalent (0.5 mL dose) Syringe	\$ 201.28 per 10 single-dose syringes
Fluzone® Trivalent (0.5 mL dose) 5 mL Vial	\$ 187.33 per multi-dose vial
MenQuadfi® (0.5 mL dose) Vial	\$ 881.79 per 5 single-dose vials
MenQuadfi® (0.5 mL dose) Vial	\$ 1,763.59 per 10 single-dose vials
NUVAXOVID™ (5 mcg/0.5 mL dose) Syringe	\$ 1,683.50 per 10 single-dose syringes
Pentacel® (0.5 mL dose) Vial Package	\$ 581.56 per 5-dose vial package
Quadracel® (0.5 mL dose) Syringe	\$ 640.37 per 10 single-dose syringes
Quadracel® (0.5 mL dose) Vial	\$ 640.37 per 10 single-dose vials
VAXELIS® (0.5 mL dose) Syringe	\$ 1,522.05 per 10 single-dose syringes
VAXELIS® (0.5 mL dose) Vial	\$ 1,522.05 per 10 single-dose vials

### Below please find as applicable three generic prescription drugs\*\*

No generics applicable to the above prescription drugs

Your patients' out of pocket cost may be different

Information on the variation efficacy of the legend (prescribed) drug marketed to different racial and ethnic groups, if such information is available, can be found in the drug's FDA approved Prescribing Information document which can be accessed at <https://www.sanofi.us/en/products-and-resources/vaccines>.

**\*Wholesale Acquisition Cost (WAC)** as published by FDB represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to FDB by the manufacturer. WAC does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price. FDB does not perform any independent investigation or analysis of actual transaction prices for purposes of reporting WAC. FDB relies on manufacturers to report or otherwise make available the values for the WAC.

For more information about First Databank's drug pricing policy, visit <https://www.fdbhealth.com/drug-pricing-policy>

**\*\*The USC (Uniform System of Classification)** Therapeutic Classification schema was used to determine similar generic drugs. The **HCFA Drug Category of "Non-Innovator Multi-source"** as supplied on the CMS (formerly HCFA) quarterly update was used to determine the generic status of the drug products. This list does not imply that the generic prescription drugs on this form are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.